Androgen receptor dependent upregulation of D-type-cyclins leading to activation of the cyclin D1/CDK4/6 complex and proliferation in prostate cancer cells suggests that targeting this axis may be effective in castration resistant prostate cancer (CRPC). Here, CDK4 is linked to prostate cancer.